BioSyntech, Inc. Engages in the development of bio-therapeutic thermogels designed for tissue repair and delivery of therapeutic agents. The company is headquartered in Laval, Quebec and currently employs 20 full-time employees. The company went IPO on 2000-01-10. The firm is developing biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The firm's platform technology is a family of hydrogels called BST-Gel, some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offers properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. The firm's lead, late-stage product, BST-CarGel is undergoing an international pivotal trial.
Follow-Up Questions
BioSyntech Inc 'in CEO'su kimdir?
Ms. Jeanne Bertonis 2010 'den beri şirketle birlikte olan BioSyntech Inc 'in Chief Executive Officer 'ıdır.
BSYI hissesinin fiyat performansı nasıl?
BSYI 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
BioSyntech Inc için ana iş temaları veya sektörler nelerdir?
BioSyntech Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
BioSyntech Inc 'in piyasa değerlemesi nedir?
BioSyntech Inc 'in mevcut piyasa değerlemesi $0 'dir
